[1] SHAO L, WANG W X, SONG Z B, et al. The efficacy and safety of anlotinib treatment for advanced lung cancer[J]. Onco Targets Ther,2019,12:6549-6554. doi:  10.2147/OTT.S205674
[2] HUANG J, XIAO J X, FANG W T, et al. Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): a randomized, double-blind, multicenter phase Ⅱ trial[J]. J Clin Oncol,2019,37(4_suppl):95. doi:  10.1200/JCO.2019.37.4_suppl.95
[3] LI D P, TANG P Z, CHEN X H, et al. Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: a multicenter, randomized, double-blind, placebo-controlled phase ⅡB trial[J]. J Clin Oncol,2019,37(15_suppl):6019. doi:  10.1200/JCO.2019.37.15_suppl.6019
[4] MA J H, SONG Y, SHOU J Z, et al. Anlotinib for patients with metastatic renal cell carcinoma previously treated with one vascular endothelial growth factor receptor-tyrosine kinase inhibitor: a phase 2 trial[J]. Front Oncol,2020,10:664. doi:  10.3389/fonc.2020.00664
[5] 戴素娟, 颜娟, 谢铮铮. 安罗替尼致视物模糊伴血压升高1例[J]. 中国现代应用药学, 2019, 36(17):2214-2216.
[6] 杜旭, 熊成欢, 龙光英, 等. 1例疑似安罗替尼致抗利尿激素分泌不当综合征患者的药学监护[J]. 肿瘤药学, 2019, 9(6):939-942, 951. doi:  10.3969/j.issn.2095-1264.2019.06.22
[7] 林宝琪, 彭秀凡, 陈鹏飞, 等. 安罗替尼联合吉非替尼治疗EGFR突变NSCLC导致严重皮下出血1例[J]. 肿瘤药学, 2019, 9(3):527-528.
[8] 刘慧, 马云飞, 刘百龙, 等. 安罗替尼联合放疗治疗复发难治小细胞肺癌1例报告及文献复习[J]. 吉林大学学报(医学版), 2020, 46(2):394-398, 436.
[9] 王文敏, 王克穷, 赵一帆, 等. 经方联合盐酸安罗替尼治疗卵巢癌晚期1例[J]. 天津中医药, 2019, 36(9):901-903.
[10] 王园姬, 张文静, 焦洋, 等. 安罗替尼致多种严重药品不良反应一例[J]. 药学服务与研究, 2020, 20(2):156-159.
[11] 谢婷婷, 王伟兰. 盐酸安罗替尼致急性心肌梗死1例[J]. 中国药物应用与监测, 2020, 17(1):62-63. doi:  10.3969/j.issn.1672-8157.2020.01.017
[12] 徐伟佳, 高勇, 吴雪. 临床药师对3例安罗替尼治疗晚期肺癌致不良反应的药学监护[J]. 中国药房, 2019, 30(19):2727-2731.
[13] 殷实, 王红红, 王荣芽. 安罗替尼致过敏性紫癜1例护理体会[J]. 中西医结合护理(中英文), 2019, 5(7):211-213.
[14] 张印印, 范凯凯, 范秀英, 等. 1例安罗替尼致患者不良反应的药学监护[J]. 世界复合医学, 2019, 5(2):56-58, 168.
[15] 朱小丽. 安罗替尼致小细胞肺癌患者间质性肺病1例[J]. 中国医院药学杂志, 2020, 40(2):240-241.
[16] 郝慧娟, 张旻, 张国清, 等. 不同机制所致的血管紊乱化生长的共同干预: 安罗替尼治疗右肺鳞癌合并血栓闭塞性脉管炎1例[J]. 中国肺癌杂志, 2020, 23(1):60-64.
[17] 张维维, 张正伟, 李小娟, 等. 安罗替尼治疗晚期双原发肺鳞癌和下咽鳞癌1例[J]. 临床肿瘤学杂志, 2019, 24(7):665-667. doi:  10.3969/j.issn.1009-0460.2019.07.020
[18] LI D, WEI G L, LI L C, et al. Bronchopleural fistula in squamous cell lung cancer following anlotinib treatment: a case report[J]. Mol Clin Oncol,2019,11(6):595-598.
[19] ZHENG Y Y, ZHOU M, ARULANANDA S, et al. Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion[J]. J Thorac Dis,2020,12(3):159-164. doi:  10.21037/jtd.2020.01.65
[20] JIANG B L, LI J H, CHEN J, et al. Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma[J]. Thorac Cancer,2020,11(2):461-464. doi:  10.1111/1759-7714.13288
[21] LV Y, ZHANG J D, LIU F J, et al. Targeted therapy with anlotinib for patient with recurrent glioblastoma: a case report and literature review[J]. Medicine,2019,98(22):e15749. doi:  10.1097/MD.0000000000015749
[22] ZHANG A X, LIU B, XU D D, et al. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: a case report[J]. Medicine,2019,98(52):e18435. doi:  10.1097/MD.0000000000018435
[23] SUN Y K, NIU W, DU F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol,2016,9(1):105. doi:  10.1186/s13045-016-0332-8
[24] ABDEL-QADIR H, ETHIER J L, LEE D S, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis[J]. Cancer Treat Rev,2017,53:120-127. doi:  10.1016/j.ctrv.2016.12.002
[25] CAMERON A C, TOUYZ R M, LANG N N. Vascular complications of cancer chemotherapy[J]. Can J Cardiol,2016,32(7):852-862. doi:  10.1016/j.cjca.2015.12.023
[26] LIU B, DING F X, LIU Y, et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients[J]. Oncotarget,2016,7(41):67661-67673. doi:  10.18632/oncotarget.11813
[27] SI X Y, ZHANG L, WANG H P, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303[J]. Thorac Cancer,2019,10(3):551-556. doi:  10.1111/1759-7714.12977
[28] TOUYZ R M, LANG N N, HERRMANN J, et al. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition[J]. Hypertension,2017,70(2):220-226. doi:  10.1161/HYPERTENSIONAHA.117.08856
[29] HAMNVIK O P R, CHOUEIRI T K, TURCHIN A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway[J]. Cancer,2015,121(2):311-319. doi:  10.1002/cncr.28972
[30] CHI Y, FANG Z W, HONG X N, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J]. Clin Cancer Res,2018,24(21):5233-5238. doi:  10.1158/1078-0432.CCR-17-3766
[31] ERYILMAZ M K, MUTLU H, SALIM D K, et al. Fatal posterior revesible leukoencephalopathy syndrome associated Coma induced by bevacizumab in metastatic colorectal cancer and review of literature[J]. J Oncol Pharm Pract,2016,22(6):806-810. doi:  10.1177/1078155215611048
[32] ESTRADA C C, MALDONADO A, MALLIPATTU S K. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities[J]. J Am Soc Nephrol,2019,30(2):187-200. doi:  10.1681/ASN.2018080853
[33] SCHMIDINGER M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors[J]. EJC Suppl,2013,11(2):172-191. doi:  10.1016/j.ejcsup.2013.07.016
[34] ZHANG K, MA X Y, GAO H J, et al. Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study[J]. Cancer Manag Res,2020,12:3409-3417. doi:  10.2147/CMAR.S246000